Actionable news
0
All posts from Actionable news
Actionable news in TRVN: TREVENA Inc,

Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society

KING OF PRUSSIA, Pa., May 11, 2016 (BUSINESS WIRE) -- Trevena, Inc. TRVN, -2.57% a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

“The clinical and scientific research presented at the American Pain Society annual meeting highlight some of the key differentiating features observed in the oliceridine phase 2 program,” said David Soergel, M.D., chief medical officer at Trevena. “In these studies, head-to-head comparisons of oliceridine to morphine suggest the potential for oliceridine to offer rapid, powerful pain relief with improved safety and tolerability compared to conventional opioid analgesics.”

Details for the poster presentations are as follows:

Title:

Rapid reduction in pain intensity with oliceridine (TRV130), a novel receptor G protein Pathway Selective modulator (-GPS), vs. Morphine

Poster Number:

433

Poster Session:

9:30-11:00am, Thursday May 12 [th]

Title:

Gastrointestinal tolerability with oliceridine (TRV130), a novel receptor G protein Pathway Selective modulator (-GPS), vs morphine

Poster Number:

435

Poster Session:

9:30-11:00am, Thursday May 12 [th]

Title:

Respiratory safety with oliceridine (TRV130), a novel receptor G protein pathway selective modulator (-GPS), vs morphine

Poster Number:

432

Poster Session:

3:45-5:15pm, Thursday May 12 [th]

Title:

Oliceridine (TRV130), a novel receptor G protein pathway selective modulator (-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic (PK/PD) model

Poster Number:

342

Poster Session:

...


More